Perturbations in the adiponectin system, as observed in patients with lung cancer, can modulate the antiproliferative and anti‐inflammatory effects mediated by adiponectin, thereby offering new therapeutic options for lung cancer patients. The gene discussed is ADIPOQ; the disease is lung cancer.